The Latest "Buzz on the Street" Show: Featuring Pressure Biosciences Inc. (OTCQB: PBIO) PCT Platform | Financial Buzz

The Latest “Buzz on the Street” Show: Featuring Pressure Biosciences Inc. (OTCQB: PBIO) PCT Platform

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Pressure BioSciences’ PCT Platform Prominently Featured in Record Number of Presentations at Major International Science Conference.”

Pressure BioSciences, Inc. (OTCQB: PBIO) announced that the Company’s patented pressure cycling technology platform was prominently featured in 15 independent presentations at the annual conference of the American Society for Mass Spectrometry, held from June 1-6, 2019 in Atlanta, GA. The presentations spanned wide ranging applications for PBI’s unique PCT platform in scientific studies, particularly their essential use in advancing knowledge and understanding in such areas as cancer research, protein function, molecular biology, and biomarker discovery.

Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant and alternating hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. 

Recently, the U.S. Food and Drug Administration held its first-ever public forum on cannabis and its derivative, CBD or cannabidiol. The FDA’s decision to hold the meeting comes after the government approved the U.S. Farm Bill, allowing for the possession, cultivation, and sale of hemp-derived CBD products. The FDA held the meeting in order to better understand and evaluate the efficacy of CBD, potentially allowing producers to add CBD into food and beverages as the agency has strictly stated that CBD currently cannot be added into food and beverages because it is still considered as a drug. However, given the strong public interest, the former FDA Commissioner Scott Gottlieb said that he is willing to hear opinions and research on the matter. Over a hundred speakers, which included researchers, health professionals, and politicians, voiced their opinions on the scientific background of CBD. Researchers have long argued that CBD can be effectively used to treat a variety of medical ailments such as cancer, chronic pain, Alzheimer’s, Parkinson’s, and notably, epilepsy. Notably, in 2018, the FDA approved the first-ever cannabis-based drug, Epidiolex, which is used to treat epilepsy among children. Following the passage of the U.S. Farm Bill, many retailers and online vendors began to sell CBD-based products. In the beginning, mostly local businesses sold these hemp-derived CBD products, but shortly after, major international corporations such as Walmart and Amazon also began to carry CBD products that are geared towards health and wellness. Looking back, regardless of concrete regulatory approval, the CBD industry has made significant progress throughout the past year. Moreover, researchers and medical institutions are continually evaluating and studying CBD in efforts to launch large scale clinical trials, potentially leading to the broader approval of CBD. According to data compiled by Ameri Research, the global legal marijuana market was valued at USD 14.3 Billion in 2016. By 2024, legal marijuana global sales are projected to reach USD 63.5 Billion while exhibiting a CAGR of 21.1% from 2017 to 2024. 

The World Health Organization (WHO) has long been an advocate for CBD. The organization released a report last year which noted that CBD is safe and is not associated with any negative public health effects. Additionally, the WHO highlighted that CBD is the non-psychoactive compound found within the cannabis plant. While the Canadian Imperial Bank of Commerce analysts cited the WHO’s report, they mentioned that there is still a lack of data in order to progress further. On the other hand, CIBC acknowledged that there is a strong growing demand for CBD, citing a speaker from at the hearing from that suggested there are about 65 million Americans who have tried CBD and 63% found it effective, according to MarketWatch. While many reputable CBD supporters praise the benefits of the compounds, most agree that there is still a need for testing and safety standards. CIBC said that it expects to hear more clarification from the FDA within the year. In the meantime, companies and researchers are expected to continue advancing and developing clinical trials to undermine the floating misconceptions and stereotypes regarding CBD. “Predicting the future of cannabis isn’t the easiest thing to do, but there are certain things that we know for a fact will happen/change,” said Arnaud Dumas de Rauly, Co-Chief Executive Officer of The Blinc Group. “The first being that Cannabis will come off Schedule 1. The majority of the industry doesn’t think this will happen within the current administration but we believe it will happen sooner than later. This will lead to a more mainstream approach to compliance and the involvement of organizations like the FDA, if they are given a mandate. Then will come a regulatory framework and we’ll be confronted with inconsistencies regarding state-level and federal regulations.”

For more information, please visit: Pressure Biosciences, Inc.

For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

2 Comments
  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pressure biosciences, inc, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.